Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
Cayman IslandsIPO:
03 February 2016Website:
http://www.beigene.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 20:34:34 GMTDividend
Analysts recommendations
Institutional Ownership
BGNE Latest News
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain in an oral session (Abstract S160). The presentation will feature data from arm D of SEQUOIA evaluating BRUKINSA in combination with venetoclax in treatment-naïve (TN) patients with high-risk chron.
DUBAI, United Arab Emirates--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclude their partnership. This strategic decision aligns with BeiGene's goals to expand its presence and directly manage operations in the MENA region. The collaboration between the two companies began in 2020 and included sales, distribution, and commercialization activities for BRUKINSA® (Zanubrutinib) in the MENA re.
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 with a fireside chat at 1:20 pm EDT. Live webcast of this event can be accessed from the investors section of BeiGene's website at http://ir.beigene.com, https://hkexir.beigene.com/, https://sseir.beigene.com/. Archived replay will be available fo.
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton's tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL) and small lym.
Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.
The U.S. Food and Drug Administration has approved BeiGene's drug to treat a type of esophageal cancer in patients who have previously received chemotherapy.
The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's combination drug to treat certain patients with a type of blood cancer, the health regulator said on Thursday.
REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.
We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
DOYU, STLA, BGNE, LEGH and WTS have been added to the Zacks Rank #1 (Strong Buy) List on December 22, 2023.
- 1(current)
What type of business is BeiGene?
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
What sector is BeiGene in?
BeiGene is in the Healthcare sector
What industry is BeiGene in?
BeiGene is in the Biotechnology industry
What country is BeiGene from?
BeiGene is headquartered in Cayman Islands
When did BeiGene go public?
BeiGene initial public offering (IPO) was on 03 February 2016
What is BeiGene website?
https://www.beigene.com
Is BeiGene in the S&P 500?
No, BeiGene is not included in the S&P 500 index
Is BeiGene in the NASDAQ 100?
No, BeiGene is not included in the NASDAQ 100 index
Is BeiGene in the Dow Jones?
No, BeiGene is not included in the Dow Jones index
When does BeiGene report earnings?
The next expected earnings date for BeiGene is 02 August 2024